Results 271 to 280 of about 25,065,433 (389)

Development of nanospray loaded with ciclopirox for dermal fungus treatment: determination of pro-inflammatory interleukin IL-2 mRNA expression. [PDF]

BMC Pharmacol Toxicol
Mehmood Y, Shahid H, Nazir R, Uddin MN, Nur-E-Alam M, Bourhia M, Almaary KS, Kazi M, Mahamat OB.   +8 more
europepmc   +1 more source

The activation of IL-2 transcription in L3T4+ and Lyt-2+ lymphocytes during virus infection in vivo. [PDF]

, 1989
Marion T. Kasaian, Christine A. Biron
openalex   +1 more source

KRAS and GNAS mutations in cell‐free DNA and in circulating epithelial cells in patients with intraductal papillary mucinous neoplasms—an observational pilot study

Molecular Oncology, EarlyView.
This study demonstrates that KRAS and GNAS mutations are more prevalent in patients with resected intraductal papillary mucinous neoplasms (IPMN) compared to those under clinical surveillance. GNAS mutations significantly differ between the two patient cohorts, indicating that their absence may serve as a potential biomarker to support conservative ...
Christine Nitschke, Marie Tölle, Philipp Walter, Kira Meißner, Mara Goetz, Jolanthe Kropidlowski, Andreas W. Berger, Jakob R. Izbicki, Felix Nickel, Thilo Hackert, Klaus Pantel, Harriet Wikman, Faik G. Uzunoglu   +12 more
wiley   +1 more source

A novel vesicular stomatitis virus armed with IL-2 mimic for oncolytic therapy. [PDF]

Virol Sin
Wu M, Wang Y, Wu C, Huang H, Zhou X, Wang J, Xiong S, Dong C.   +7 more
europepmc   +1 more source

On‐treatment dynamics of circulating extracellular vesicles in the first‐line setting of patients with advanced non‐small cell lung cancer: the LEXOVE prospective study

Molecular Oncology, Volume 19, Issue 5, Page 1422-1435, May 2025.
The LEXOVE prospective study evaluated plasma cell‐free extracellular vesicle (cfEV) dynamics using Bradford assay and dynamic light scattering in metastatic non‐small cell lung cancer patients undergoing first‐line treatments, correlating a ∆cfEV < 20% with improved median progression‐free survival in responders versus non‐responders.
Valerio Gristina, Viviana Bazan, Nadia Barraco, Simona Taverna, Mauro Manno, Samuele Raccosta, Anna Paola Carreca, Marco Bono, Tancredi Didier Bazan Russo, Francesco Pepe, Pasquale Pisapia, Lorena Incorvaia, Giuseppe Badalamenti, Giancarlo Troncone, Umberto Malapelle, Daniele Santini, Antonio Russo, Antonio Galvano   +17 more
wiley   +1 more source

A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells. [PDF]

Commun Biol
Lin Y, Wang X, Qin Y, Wang C, Zhou T, Zhang L, Su L, Ren W, Liao C.   +8 more
europepmc   +1 more source

Inhibiton of IL 2 production after human allogeneic bone marrow transplantation. [PDF]

, 1983
Orly Azogui, Éliane Gluckman, D Fradelizi   +2 more
openalex   +1 more source

Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer

Molecular Oncology, Volume 19, Issue 4, Page 1155-1169, April 2025.
We propose an efficient strategy to suppress ALK inhibitor (ALKi) resistance. By analyzing transcriptome data, we identified emetine as a potential inhibitor. We demonstrated that emetine exhibited effectiveness in inhibiting the growth of ALKi‐resistant cells, and further interpreted its impact on the resistant signatures through drug‐induced RNA ...
Sang‐Min Park, Keeok Haam, Haejeong Heo, Doyeong Kim, Min‐Ju Kim, Hyo‐Jung Jung, Seongwon Cha, Mirang Kim, Haeseung Lee   +8 more
wiley   +1 more source

Metabolic impact of low dose IL-2 therapy for primary Sjögren's Syndrome in a double-blind, randomized clinical trial. [PDF]

Clin Rheumatol
Feng R, Xiao X, Wang Y, Huang B, Chen J, Cheng G, Jin Y.   +6 more
europepmc   +1 more source

rIL 2-induced proliferation of human circulating NK cells and T lymphocytes: synergistic effects of IL 1 and IL 2. [PDF]

, 1987
M.H. Ben Aribia, E Leroy, Olivier Lantz, David Métivier, Brigitte Autran, B Charpentier, T Hercend, A Senik   +7 more
openalex   +1 more source